MKI67 and head and neck squamous cell carcinoma: Immunohistochemical studies on biopsies of patients with advanced HNSCC who received nimotuzumab has shown a reduction in proliferation index (P = 0.012) and Ki-67 was expression mainly in the infiltrating borders of the tumors [24].